

Ministry of Health

Application for Prior Approval for Full Payment of Insured Out-of-Country (OOC) & Out-of-Province (OOP) Laboratory & Genetics Testing Services

Ineligible Tests or Testing

The following tests or testing are currently ineligible for funding through the OOC/OOP PA program:

- Broad pharmacogenomic panel testing
- Expanded Carrier Screening (ECS), including any subsequent testing of partners based on ECS results
- Hereditary Lymphoid Malignancy/Immunodeficiency Predisposition panels (excluding select purposes to guide patient management decisions – see ministry guidance)
- MaterniT Genome Test
- Repeat testing of a gene panel test within 3 years (excluding testing for monitoring purposes)
- RNA testing (excluding NF1 RNA testing for certain purposes – see ministry guidance)
- Whole Genome Sequencing (WGS), Transcriptomes, Proteomes, Metabolomes
- Targeted testing to confirm or segregate genetic variants of uncertain significance (VUS) or genetic variants in genes of uncertain significance (GUS), identified from research studies
- Multigene tumor profiling tests for myeloma (e.g., SKY92)
- Multigene tumor profiling tests for breast cancer (excluding tests for inform chemotherapy treatment – see ministry guidance) (e.g., DCISionRT)

Note: This document is technical in nature and is available in English only due to its limited targeted audience. This publication has been exempted from translation under the *French Language Services Act*.

Remarque: Ce document est de nature technique et est disponible en anglais uniquement en raison de son public cible limité. Ce document a été exempté de la traduction en vertu de la *Loi sur les services en français*.